Showing results (1-10 of 441) with videos related to
Sort By:
Pageof 45
Biopharmaceutics & Drug Disposition|November 1, 1986
Mechanism for the interaction between triazolam and cimetidineS R Cox, P D Kroboth, P H Anderson, et al.Psychopharmacology|January 1, 1987
Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effectsR B Smith, P D KrobothThe Journal of Pharmacology and Experimental Therapeutics|March 1, 1993
Acute tolerance to triazolam during continuous and step infusions: estimation of the effect offset rate constantP D Kroboth, R J Bertz, R B SmithClinical Pharmacology and Therapeutics|March 1, 1988
Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effectsP D Kroboth, R B Smith, R J ErbJournal of Clinical Pharmacology|December 1, 1987
Pharmacodynamics of triazolam after intravenous administrationR B Smith, P D Kroboth, P D VarnerDrug Intelligence & Clinical Pharmacy|January 1, 1987
The clinical pharmacist in drug research and development. An academic-industrial centerR B Smith, P D Kroboth, R P JuhlPsychopharmacology|January 1, 1990
Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosingP D Kroboth, J W McAuley, R B SmithJournal of Clinical Pharmacology|February 1, 1986
Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administrationR B Smith, P D Kroboth, J P PhillipsJournal of Chromatography|July 17, 1991
New high-performance liquid chromatographic method for the determination of alprazolam and its metabolites in serum: instability of 4-hydroxyalprazolamV D Schmith, S R Cox, M A Zemaitis, et al.Journal of Clinical Pharmacology|June 1, 1991
Alprazolam in end-stage renal disease: I. PharmacokineticsV D Schmith, B Piraino, R B Smith, et al.Pageof 45